– StartX company, Eko, announced today that the FDA has cleared Eko’s AFib and heart murmur detection algorithms, making it the first AI-powered stethoscope to screen for serious heart conditions.
– Eko’s algorithms alert clinicians to the presence of heart murmurs and atrial fibrillation (AFib) during the physical exam, converting the classic stethoscope into a powerful early detection tool.
Eko, a digital health company applying artificial intelligence (AI) in the fight against heart disease, announced today that the U.S. Food and Drug Administration has cleared a suite of algorithms that, when combined with Eko’s digital stethoscopes will enable healthcare providers in the U.S. to more accurately screen for heart conditions during routine physical exams. If left undiagnosed, these heart conditions can lead to stroke and heart failure.
Why It Matters
Patients with valvular heart disease and AFib often go undiagnosed during the physical exam. Murmurs indicative of valvular or structural heart disease can be extremely difficult for clinicians to hear and AFib may not be detected during the physical exam. AFib is an irregular and often rapid heartbeat that is often asymptomatic and can lead to blood clots, strokes, heart failure, and other heart-related complications.
Eko’s AI is a cloud-based software application that analyzes ECG and heart sound/phonocardiogram (PCG) data. The software uses several methods to interpret the acquired signals, including signal processing and convolutional neural networks. The software is intended to provide support to the physician in the evaluation of patients’ heart sounds and ECGs. Eko’s AI is able to identify heart murmurs, a leading symptom of valvular heart disease, with 87% sensitivity and 87% specificity. In comparison, a recent study revealed that using traditional stethoscopes, primary care physicians had a sensitivity of 43% and a specificity of 69% for detecting significant valvular heart disease, which affects over 5 million Americans.
Eko’s AI Detection Outcomes
The AI is able to detect AFib with 99% sensitivity and 97% specificity when analyzing the 1-lead ECG tracing from the Eko DUO stethoscope. The integration of ECG into the stethoscope enables providers to quickly screen patients for the serious arrhythmia during a standard physical exam. The Algorithm also reports heart rate and QRS duration and identifies tachycardia and bradycardia, abnormally fast and slow heart rates, which can be indicative of heart disease or other health conditions such as thyroid disease.
Eko’s AFib and Murmur Screening Algorithms
Eko’s AFib and Murmur screening algorithms are the first in a suite of cardiac screening algorithms Eko plans to combine with its digital stethoscope devices to assist providers in the detection of cardiovascular conditions. In December 2019, Eko announced the FDA had granted the company breakthrough status for a novel ECG-based algorithm that, if FDA-cleared, could provide an easily accessible screening test for heart failure. Since the release of its first-generation Eko CORE device in 2015, Eko’s technology has been adopted by clinicians at more than 4,000 hospitals and clinics in the U.S. and Europe.
“Our vision since day one has been to build seamless technology that helps providers more accurately detect heart disease, the leading killer in the world, by putting the ears of a cardiologist in any clinician’s stethoscope,“ says Connor Landgraf, Eko’s Co-Founder and CEO. “Eko’s new ability to alert a provider to the presence of a heart murmur or atrial fibrillation during the standard physical exam brings that vision to life.”